内科学
内分泌学
磷酸西他列汀
胰岛素抵抗
脂肪变性
胰岛素
葡萄糖稳态
糖耐量受损
2型糖尿病
甘油三酯
糖耐量试验
脂肪肝
医学
生物
糖尿病
化学
胆固醇
疾病
作者
Bárbara Maiztegui,María Inés Borelli,Viviana Madrid,Hector Herminio del Zotto,María Agustina Raschia,Flavio Francini,María Laura Massa,Luis Flores,Oscar R. Rebolledo,Juan José Gagliardino
出处
期刊:Clinical Science
[Portland Press]
日期:2010-10-08
卷期号:120 (2): 73-80
被引量:62
摘要
The aim of the present study was to test the effect of sitagliptin and exendin-4 upon metabolic alterations, β-cell mass decrease and hepatic steatosis induced by F (fructose) in rats. Normal adult male Wistar rats received a standard commercial diet without (C) or with 10% (w/v) F in the drinking water (F) for 3 weeks; animals from each group were randomly divided into three subgroups: untreated (C and F) and simultaneously receiving either sitagliptin (CS and FS; 115.2 mg/day per rat) or exendin-4 (CE and FE; 0.35 nmol/kg of body weight, intraperitoneally). Water and food intake, oral glucose tolerance, plasma glucose, triacylglycerol (triglyceride), insulin and fructosamine concentration, HOMA-IR [HOMA (homoeostasis model assessment) for insulin resistance], HOMA-β (HOMA for β-cell function) and liver triacylglycerol content were measured. Pancreas immunomorphometric analyses were also performed. IGT (impaired glucose tolerance), plasma triacylglycerol, fructosamine and insulin levels, HOMA-IR and HOMA-β indexes, and liver triacylglycerol content were significantly higher in F rats. Islet β-cell mass was significantly lower in these rats, due to an increase in the percentage of apoptosis. The administration of exendin-4 and sitagliptin to F animals prevented the development of all the metabolic disturbances and the changes in β-cell mass and fatty liver. Thus these compounds, useful in treating Type 2 diabetes, would also prevent/delay the progression of early metabolic and tissue markers of this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI